Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HMPL-689 in Healthy Volunteers
NCT02631642Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Mar 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in B cell lymphoma comparing HMPL-689 with Placebo (2 arms). Primary endpoint: Dose Limited Toxicities at 28 days. Started Mar 2016; status: completed.
02
Drugs
amdizatinib
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT02631642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02631642.